APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
Granted: January 5, 2012
Application Number:
20120004267
The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, R, R1, R2 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD,…
METHODS FOR TREATING HCV
Granted: December 15, 2011
Application Number:
20110306541
This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
1'SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Granted: December 1, 2011
Application Number:
20110293563
Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
ANTIVIRAL PHOSPHONATE ANALOGS
Granted: November 24, 2011
Application Number:
20110288053
The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
BI-FUNCTIONAL QUINOLINE ANALOGS
Granted: November 10, 2011
Application Number:
20110275622
Provided are compounds of Formula I: wherein X is: R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.
BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS
Granted: November 10, 2011
Application Number:
20110275623
This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.
A2B ADENOSINE RECEPTOR ANTAGONISTS
Granted: October 20, 2011
Application Number:
20110257127
Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
MODULATORS OF TOLL-LIKE RECEPTOR 7
Granted: September 29, 2011
Application Number:
20110236348
The present invention includes therapeutic methods that include the administration of a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, to a subject in need of such, and therapeutic methods that include the administration of such compounds with at least one additional active agent.
FOSFOMYCIN/TOBRAMYCIN COMBINATIONS FOR THE TREATMENT AND PREVENTION OF OPHTHALMIC, OTOLOGICAL AND DERMATOLOGICAL INFECTIONS
Granted: September 22, 2011
Application Number:
20110230431
Provided are topical fosfomycin-tobramycin compositions for the treatment and/or prevention of ophthalmic, otological, and dermatologic inflammation and/or bacterial infections and methods of treating ophthalmic, otological and dermatological inflammation and/or bacterial infections.
PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS
Granted: September 22, 2011
Application Number:
20110230654
Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,24][1,2,4]triazinyl heterocycles of Formula I.
ANTIVIRAL COMPOUNDS
Granted: September 15, 2011
Application Number:
20110223131
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Nucleic Acid Ligand Complexes
Granted: September 1, 2011
Application Number:
20110212030
This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a…
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: September 1, 2011
Application Number:
20110212964
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
High Affinity Nucleic Acid Ligands of Complement System Proteins
Granted: August 11, 2011
Application Number:
20110196021
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
Granted: July 28, 2011
Application Number:
20110184002
The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
INHIBITORS OF FLAVIVIRIDAE VIRUSES
Granted: July 21, 2011
Application Number:
20110178058
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
INHIBITORS OF FLAVIVIRIDAE VIRUSES
Granted: July 21, 2011
Application Number:
20110178129
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN
Granted: July 14, 2011
Application Number:
20110171196
The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment…
METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES
Granted: July 14, 2011
Application Number:
20110172192
A compound of formula 1 and/or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate.
PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS
Granted: June 30, 2011
Application Number:
20110160162
Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.
